Tapering off a peptide cycle vs cold-stop

The way you end a peptide cycle matters more than most beginners realize. For some compounds — BPC-157, TB-500, KPV — you can finish the last injection on a Tuesday and be done. For others — GH secretagogues, MK-677, anything that's been pushing an endogenous axis — cold-stopping can produce a noticeable rebound week or two later that lifters often misattribute to "the gains are gone." Knowing which compounds need a taper and which don't lets you preserve the benefits of a cycle, avoid the rebound, and plan the next cycle without the unnecessary fade in between.

Why the question even exists

Peptides fall into roughly two categories at the end of a cycle.

Direct-acting compounds do something at the tissue level and stop doing it when the molecule clears. BPC-157 promotes angiogenesis and growth-factor signaling at the injection site; when you stop injecting, the promotion stops, and the new tissue you've built persists. There's no axis to rebound. Cold-stop is fine.

Axis-modulating compounds push an endogenous system that adapts to the push. GH secretagogues elevate GH and IGF-1 levels above the body's baseline; over a multi-week cycle, the body's regulatory feedback adjusts to that new normal. When you cold-stop, the elevated baseline drops fast, but the regulatory adaptation persists for a while — meaning your endogenous output can be temporarily suppressed below where it started.

That's the rebound. It's not dangerous in any clinical sense for most strength peptides. It is meaningful for users who experience it as "my recovery got worse the week after I stopped" and don't realize they're on the downslope of an adaptation curve, not a permanent change.

The peptides that don't need a taper

You can cold-stop these without consequence:

For all of these, your last injection of the cycle is just your last injection. There's no taper protocol, no PCT-style follow-up, nothing to manage on the back end. You stop, the compound clears, you go.

This is one reason BPC-157 is the standard recommendation as a first peptide. It's simple to start and simple to stop. See easiest peptide for beginners.

The peptides that benefit from a taper

The list of peptides that produce some kind of rebound or adaptation at the end of a cycle:

The peptide that most consistently benefits from tapering is MK-677. The effects on hunger, water retention, sleep architecture, and IGF-1 levels build over weeks and persist briefly after the last dose. Cold-stopping after a 12-week MK-677 cycle reliably produces 1–2 weeks of degraded sleep, increased hunger volatility, and feeling generally "off." Tapering the dose down over the final 2 weeks reduces this dramatically.

What a taper actually looks like

Tapers aren't complicated. The pattern is consistent across compounds: reduce dose by ~50% for the final 1–2 weeks, then stop.

MK-677 example:

• Weeks 1–10 at 15 mg/day
• Weeks 11–12 at 7.5 mg/day
• Stop

Tesamorelin example:

• Weeks 1–10 at 2 mg/day
• Weeks 11–12 at 1 mg/day
• Stop

Ipamorelin + CJC-1295 (long cycle) example:

• Weeks 1–10 at full dose (e.g., 250 mcg ipa + 200 mcg CJC pre-bed)
• Weeks 11–12 at half dose
• Stop

The taper does two things: gives the regulatory feedback time to start unwinding before the endogenous push disappears, and reduces the magnitude of the post-cycle drop the user actually feels. It doesn't extend the "benefit" of the cycle in any meaningful way — once the compound clears, the direct effects are over either way.

Why the rebound happens

Worth explaining briefly because it changes how users should think about the post-cycle window.

GH secretagogues and similar axis-active peptides work by adding an external push to a regulated system. The hypothalamic-pituitary axis runs on negative feedback: high circulating GH and IGF-1 reduce the natural drive to release more. Over a multi-week cycle, the natural drive turns down because external GH/IGF-1 is taking up the slack.

When you cold-stop, the external push disappears immediately, but the suppressed natural drive doesn't snap back instantly. There's a window — typically 1–3 weeks — where total GH/IGF-1 output is below where it started. This is the rebound. It resolves on its own, but during the window, users feel a noticeable dip in recovery, sleep quality, and subjective wellbeing.

For most strength peptide users, the rebound is mild and clinically irrelevant. For longer or higher-dose cycles, it's pronounced enough that the post-cycle period — often called the "PCT window" by analogy to anabolic steroid PCT, though the mechanisms differ — needs to be planned for. See PCT after a peptide cycle for more on this framing.

Planning the next cycle

The rebound window also matters for cycle planning. If you cold-stop a GH secretagogue cycle and immediately start another peptide, you're stacking onto a temporarily suppressed endogenous baseline. That's not catastrophic, but it does mean:

• The new peptide's effects will be smaller than they would be on a fully recovered baseline
• It's harder to evaluate whether the new peptide is doing anything because the baseline is moving
• You're essentially extending the same axis-disruption window

A better approach is to plan a meaningful gap between cycles — typically at least the cycle length, often double — to let the axis recover before the next push. See how long between peptide cycles for the practical framework, and multiple peptide cycles per year for the broader scheduling discussion.

What to do at the end of every cycle

A short checklist that covers most situations:

1. Identify which category your peptide falls into. Direct-acting (no taper needed) vs axis-modulating (taper helpful).
2. For axis-modulating compounds, plan a 1–2 week half-dose taper before the cycle ends.
3. Continue protective peptides through the transition. BPC-157 in particular is fine to keep running through and after the GH/IGF-1 portion of a stack — connective-tissue support during the rebound window is genuinely useful. See stacking IGF-1 LR3 with BPC-157.
4. Pull post-cycle labs after the rebound window has passed — typically 2–3 weeks after the last dose. Pulling labs immediately after the last injection captures the cycle's high-water mark, not your true recovered baseline.
5. Plan the gap before the next cycle. Don't stack one cycle straight into another without a recovery window unless you have a specific reason and have already established baseline tolerance.

The end of a cycle is the most-undermanaged part of the protocol for most users. Lifters spend weeks researching dosing and stacking, then end the cycle with no plan and wonder why their recovery feels worse for a week. The asymmetry between effort spent on the start versus the end is one of the easiest things to fix in a peptide protocol — and one of the highest-leverage.

Related reading

• How long between peptide cycles?
• Multiple peptide cycles per year?
• PCT after a peptide cycle
• Cycle peptides forever?
• Mistakes that derail first peptide cycles